CN117715648A - 靶向uPAR的抗原识别受体和其用途 - Google Patents

靶向uPAR的抗原识别受体和其用途 Download PDF

Info

Publication number
CN117715648A
CN117715648A CN202280051494.9A CN202280051494A CN117715648A CN 117715648 A CN117715648 A CN 117715648A CN 202280051494 A CN202280051494 A CN 202280051494A CN 117715648 A CN117715648 A CN 117715648A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280051494.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·W·洛
M·塞德莱恩
C·阿莫尔维加斯
P·鲍尔德里斯
I·C·洛伦兹
张则达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer And Related Diseases Memorial Hospital
Sloan Caitlin Cancer Research Association
Three Institution Treatment Discovery Institute Inc
Memorial Sloan Kettering Cancer Center
Original Assignee
Cancer And Related Diseases Memorial Hospital
Sloan Caitlin Cancer Research Association
Three Institution Treatment Discovery Institute Inc
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer And Related Diseases Memorial Hospital, Sloan Caitlin Cancer Research Association, Three Institution Treatment Discovery Institute Inc, Memorial Sloan Kettering Cancer Center filed Critical Cancer And Related Diseases Memorial Hospital
Publication of CN117715648A publication Critical patent/CN117715648A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280051494.9A 2021-06-11 2022-06-10 靶向uPAR的抗原识别受体和其用途 Pending CN117715648A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209924P 2021-06-11 2021-06-11
US63/209,924 2021-06-11
PCT/US2022/032948 WO2022261398A1 (en) 2021-06-11 2022-06-10 Antigen recognizing receptors targeting upar and uses thereof

Publications (1)

Publication Number Publication Date
CN117715648A true CN117715648A (zh) 2024-03-15

Family

ID=84425514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280051494.9A Pending CN117715648A (zh) 2021-06-11 2022-06-10 靶向uPAR的抗原识别受体和其用途

Country Status (7)

Country Link
US (1) US20240131070A1 (enExample)
EP (1) EP4351601A4 (enExample)
JP (1) JP2024520802A (enExample)
CN (1) CN117715648A (enExample)
AU (1) AU2022287975A1 (enExample)
CA (1) CA3221342A1 (enExample)
WO (1) WO2022261398A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026086712A1 (en) * 2024-10-22 2026-04-30 Peking University Upar targeting chimeric antigen receptors and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261403A1 (en) * 2021-06-11 2022-12-15 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting upar and uses thereof
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568428C (en) * 2004-05-25 2020-12-29 Attenuon, Llc Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US20220098320A1 (en) * 2019-02-01 2022-03-31 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
CN110343665B (zh) * 2019-05-05 2023-07-14 吉林大学 一种car-t细胞及其应用
WO2022261403A1 (en) * 2021-06-11 2022-12-15 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting upar and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026086712A1 (en) * 2024-10-22 2026-04-30 Peking University Upar targeting chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
EP4351601A1 (en) 2024-04-17
EP4351601A4 (en) 2025-07-02
AU2022287975A9 (en) 2024-01-25
AU2022287975A1 (en) 2023-12-14
JP2024520802A (ja) 2024-05-24
US20240131070A1 (en) 2024-04-25
CA3221342A1 (en) 2022-12-15
WO2022261398A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
US12291561B2 (en) Antigen binding receptors specific for mutated Fc domains
JP7742773B2 (ja) Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
CN107208047B (zh) 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
CA3215864A1 (en) Bispecific binding agent-ligand fusions for the degradation of target proteins
CN110461360A (zh) 改进的抗原结合受体形式
US20240123069A1 (en) Antigen recognizing receptors targeting upar and uses thereof
CN116507640A (zh) 改善的抗原结合受体
CN111484563B (zh) 一种抗cd38嵌合抗原受体及其应用
US20240131070A1 (en) Antigen recognizing receptors targeting upar and uses thereof
CN115916823A (zh) 人cd45rc特异的嵌合抗原受体及其用途
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
WO2023020537A1 (zh) 一种双特异性抗体及其用途
WO2023125813A1 (zh) 抗间皮素纳米抗体嵌合抗原受体及其应用
JP2025512797A (ja) 改善されたキメラ受容体
US20230303705A1 (en) Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
US20260034241A1 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
HK40128378A (zh) 对δ样配体3(DLL3)具有特异性的抗体和嵌合抗原受体
CN118359730A (zh) 包含细胞因子的靶向型融合蛋白
TW202600600A (zh) Egfr特異性抗原結合蛋白與細胞介素的偶聯物
Fellermeier Bifunctional immunostimulatory fusion proteins for therapeutic applications
HK40001773A (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination